Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.

Tour Hekla

Tour Hekla clinical programs — 27 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
Status
Public
HQ
Puteaux, Ile de France 92800, FR
Employees
6
Programs
27
Drugs
71
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Tour Hekla projects

27 ClinicalTrials.gov programs sponsored by Tour Hekla.

Tour Hekla has 27 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

27 programs

Clinical programs

  1. DR200091

    Tour Hekla

    Thrombotic episodes in superficial venous malformations in children

    phase 3 small molecule active

    1 trial

  2. DR230005

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  3. DR230297

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  4. DR230333

    Tour Hekla

    Intersitial lung disease related to systemic sclerosis

    phase 3 small molecule active

    1 trial

  5. DR240020

    Tour Hekla

    Hypoxemic acute respiratory failure

    phase 3 small molecule active

    1 trial

  6. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Tour Hekla

    Benign Prostate Hyperplasia

    phase 3 small molecule active

    1 trial

  7. PEDIADEX

    Tour Hekla

    Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

    phase 3 small molecule active

    1 trial

  8. PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN

    Tour Hekla

    Recurrent Erysipelas in lower limbs

    phase 3 small molecule active

    1 trial

  9. PROTO-BRAIN

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  10. RIPH_2019_01

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

  11. DR220204

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  12. DR220214

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  13. DR230070

    Tour Hekla

    Prevention of post-traumatic stress disorder

    phase 2 small molecule active

    1 trial

  14. DR230330 – ANRS0514s

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  15. IVAMI

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  16. KALINOX 50%/50% for Treatment of suicidal ideation

    Tour Hekla

    Treatment of suicidal ideation

    phase 2 small molecule active

    1 trial

  17. OPDIVO for Unresectable locally advanced o…

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  18. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  19. SOGUG2020IEC(VEJ)11

    Tour Hekla

    Muscle-invasive bladder cancer (MIBC)

    phase 2 small molecule active

    1 trial

  20. TOUR006-T01

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  22. Xarelto 2.5 mg film-coated tablets

    Tour Hekla

    Chronic hemodialysis

    phase 2 small molecule active

    1 trial

  23. CARVECIR

    Tour Hekla

    Asymptomatic Child-Pugh A5 to B8 cirrhosis

    approved small molecule active

    1 trial

  24. DR200090

    Tour Hekla

    Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening

    approved small molecule active

    1 trial

  25. DR230314

    Tour Hekla

    Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.

    approved small molecule active

    1 trial

  26. DR240305

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

  27. PHARBEVACOL

    Tour Hekla

    1st line treatment for unresectable metastatic colorectal cancer

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Tour Hekla have?

27 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.